Back to Search
Start Over
Stimulating STING for cancer therapy: Taking the extracellular route.
- Source :
-
Cell Chemical Biology . May2024, Vol. 31 Issue 5, p851-861. 11p. - Publication Year :
- 2024
-
Abstract
- Ten years ago, the second messenger cGAMP was discovered as the activator of the anti-cancer STING pathway. The characterization of cGAMP's paracrine action and dominant extracellular hydrolase ENPP1 cemented cGAMP as an intercellular immunotransmitter that coordinates the innate and adaptive immune systems to fight cancer. In this Perspective, I look back at a decade of discovery of extracellular cGAMP biology and drug development aiming to supply or preserve extracellular cGAMP for cancer treatment. Reviewing our understanding of the cell type-specific regulatory mechanisms of STING agonists, including their transporters and degradation enzymes, I explain on a molecular and cellular level the successes and challenges of direct STING agonists for cancer therapy. Based on what we know now, I propose new ways to stimulate the STING pathway in a manner that is not only cancer specific, but also cell type specific to fully harness the anti-cancer effect of cGAMP while avoiding collateral damage. Li recounts the characterization of the second messenger cGAMP as a key intercellular innate immune transmitter and development of its pharmacological analogs. Cell type-specific cGAMP transporters, hydrolases, and regulators together tightly regulate the paracrine cGAMP-STING signaling that can be harnessed to activate our powerful anti-cancer immune system. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 24519456
- Volume :
- 31
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Cell Chemical Biology
- Publication Type :
- Academic Journal
- Accession number :
- 177200847
- Full Text :
- https://doi.org/10.1016/j.chembiol.2024.04.004